Skip to content
Home/Companies/Biotech/TWIST Bioscience

TWIST Bioscience

Biotech·US·Exited 2020·Held 7yr
Entry
2013
Hold
7yr
Exit
2020

Who owns TWIST Bioscience?

TWIST Bioscience is an American Biotech company, formerly owned by Merieux Equity Partners, exited in 2020 (exit via IPO). No current private equity owner is on file.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Merieux Equity Partners
Investor
Merieux Equity Partners
Mérieux Innovation 1 · 2014 · VC

Key facts

HQUS
SectorBiotech
StatusAcquired
Exit Type
IPO
Buyer
Nasdaq listing (TWST)
Exit Year
2020

More from Mérieux Innovation 1

Other portfolio companies in the same fund.

Broken String Biosciences
Broken String Biosciences
Active
BiotechUK· 2023
InnoSyn
InnoSyn
Active
PharmaNetherlands· 2023
LabQuality
LabQuality
Exited 2025
HealthcareFrance· 2023
to Aurevia
Cairdac
Cairdac
Active
MedTechFrance· 2022
Mablink Bioscience
Exited 2023
BiotechFrance· 2022
to Eli Lilly and Company
SeqOne Genomics
SeqOne Genomics
Active
BiotechFrance· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns TWIST Bioscience?

TWIST Bioscience was formerly owned by Merieux Equity Partners, exited in 2020. No current private equity owner is on file.

Who did TWIST Bioscience sell to?

Merieux Equity Partners sold TWIST Bioscience to Nasdaq listing in 2020 (IPO).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue